Status:
RECRUITING
Optimal Non-invasive Brain Stimulation for Peripheral Vision
Lead Sponsor:
The Hong Kong Polytechnic University
Collaborating Sponsors:
Chinese University of Hong Kong
The University of Hong Kong
Conditions:
Glaucoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Glaucoma is a complex disease that can result in progressive vision loss. There are no treatments that restore vision lost to glaucoma. However, recent studies have shown that vision can be improved b...
Detailed Description
This study uses a within-subjects, double-blind, placebo-controlled design and will be carried out in Hong Kong (The Hong Kong Polytechnic University). Participants who will be recruited are 40 glauc...
Eligibility Criteria
Inclusion
- Age range from 18 to 80 years;
- Diagnosis of primary open angle or normal tension glaucoma with relative scotoma in both eyes;
- A relative scotoma defined as a Humphrey Field Analyser (HFA) threshold perimetry loss (mean deviation of ≤-6dB) within the central 30° of the visual field for at least one eye;
- Best-corrected distance visual acuity of 6/12 or better (equivalent to 0.3 logMAR acuity or better to confirm that participant's central vision is preserved);
- Stable vision and visual field loss for at least 3 months;
- With a cognitive functional score of 22 or above in the Montreal Cognitive Assessment - Hong Kong version (HK-MoCA) (to confirm participant's intact cognitive function).
Exclusion
- Ocular diseases other than glaucoma (e.g. age-related macular degeneration, diabetic retinopathy, moderate to severe cataract) or severe hearing impairment (to ensure that participant can hear the instructions clearly during assessments and training);
- Severe medical problems (e.g. stroke, Parkinson's disease) or self-reported neurological (e.g. brain surgery, brain tumor, peripheral neuropathy), or cognitive disorders (e.g. diagnosed dementia or cognitive impairment);
- Self-reported vestibular or cerebellar dysfunction, history of vertigo;
- Using any medications for any neurological conditions or psychiatric drugs (e.g. sedative, hypnotic) that might interfere with motor control;
- Contraindications for non-invasive brain stimulation.
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04846140
Start Date
November 1 2021
End Date
September 1 2025
Last Update
October 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allen MY Cheong
Hong Kong, China